Business
BIOQUAL Presents Unaudited Financial Results for First Quarter of Fiscal Year 2021
BIOQUAL Presents Unaudited Financial Results for First Quarter of Fiscal Year 2021.
About this update from Bioqual, Inc.
[{"type":"text","content":"\nBIOQUAL, Inc. (OTC Pink: BIOQ) (www.bioqual.com):\n\n\n\n\nThree Months Ended\nAugust 31,\n\n\n\n\n\n\n \n\n\n\n2020\n\n\n \n\n2019\n\n\n\n \n\n\n\n\n\n \n\n\n\n \n\n\n \n\n \n\n\n\n \n\n\n\n\n\nRevenue\n\n\n\n$\n\n\n\n14,920,475\n\n\n \n\n$\n\n\n\n10,067,876\n\n\n\n \n\n\n\n\n\n\n\n \n\n\n \n\n\n\nIncome Before Income Tax\n\n\n\n$\n\n\n\n2,496,988\n\n\n \n\n$\n\n\n\n1,874,483\n\n\n\n \n\n\n\n\n\n\n\n \n\n\n \n\n\n\nNet Income\n\n\n\n$\n\n\n\n1,766,588\n\n\n \n\n$\n\n\n\n1,324,483\n\n\n\n \n\n\n\n\n\n\n\n \n\n\n \n\n\n\nBasic Earnings per Share\n\n\n\n \n\n\n\n \n\n\n \n\n \n\n\n\n \n\n\n\n \n\n\n\n\n\nof Common Stock\n\n\n\n$\n\n\n\n1.98\n\n\n \n\n$\n\n\n\n1.48\n\n\n\n\n\n\n\n\n \n\n\n \n\n\n\nDiluted Earnings per Share\n\n\n\n \n\n\n\n \n\n\n \n\n \n\n\n\n \n\n\n\n \n\n\n\n\n\nof Common Stock\n\n\n\n$\n\n\n\n1.98\n\n\n \n\n$\n\n\n\n1.48\n\n\n\n\n\n\n\n\n \n\n\n \n\n\n\nWeighted Average\n\n\n\n \n\n\n\n \n\n\n \n\n \n\n\n\n \n\n\n\n \n\n\n\n\n\nNumber of Shares Outstanding\n\n\n\n \n\n\n\n \n\n\n \n\n \n\n\n\n \n\n\n\n \n\n\n\n\n\nFor Basic Earnings Per Share\n\n\n\n \n\n\n\n893,416\n\n\n \n\n \n\n\n\n893,416\n\n\n\n\n\n\n\n\n \n\n\n \n\n\n\nWeighted Average\n\n\n\n \n\n\n\n \n\n\n \n\n \n\n\n\n \n\n\n\n \n\n\n\n\n\nNumber of Shares Outstanding\n\n\n\n \n\n\n\n \n\n\n \n\n \n\n\n\n \n\n\n\n \n\n\n\n\n\nFor Diluted Earnings Per Share\n\n\n\n \n\n\n\n894,030\n\n\n \n\n \n\n\n\n893,648\n\n\n\n\n\nFor more detail related to the fiscal year 2021 unaudited first quarter results, please visit our web site at www.bioqual.com.\n\nStatements herein that are not descriptions of historical facts are forward-looking and subject to risks and uncertainties. Actual results could differ materially from those currently anticipated due to a number of factors including risks relating to the ability to continue to extend current government contracts; the Company’s ability to obtain new government or commercial contracts; continued demand for the use of animal models in scientific research; the Com...